AR227201A1 - Procedimiento para preparar polvo capaz de ser reconstituido mediante el agregado de agua para dar una suspension farmaceuticamente microcapsulas de sal de adicion de acido de bacampicilina en un medio de suspension acuosa - Google Patents

Procedimiento para preparar polvo capaz de ser reconstituido mediante el agregado de agua para dar una suspension farmaceuticamente microcapsulas de sal de adicion de acido de bacampicilina en un medio de suspension acuosa

Info

Publication number
AR227201A1
AR227201A1 AR286473A AR28647381A AR227201A1 AR 227201 A1 AR227201 A1 AR 227201A1 AR 286473 A AR286473 A AR 286473A AR 28647381 A AR28647381 A AR 28647381A AR 227201 A1 AR227201 A1 AR 227201A1
Authority
AR
Argentina
Prior art keywords
water
suspension
reconstituted
pharmaceutically
give
Prior art date
Application number
AR286473A
Other languages
English (en)
Spanish (es)
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Application granted granted Critical
Publication of AR227201A1 publication Critical patent/AR227201A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cephalosporin Compounds (AREA)
AR286473A 1980-08-22 1981-08-19 Procedimiento para preparar polvo capaz de ser reconstituido mediante el agregado de agua para dar una suspension farmaceuticamente microcapsulas de sal de adicion de acido de bacampicilina en un medio de suspension acuosa AR227201A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US06/180,537 US4321253A (en) 1980-08-22 1980-08-22 Suspension of microencapsulated bacampicillin acid addition salt for oral, especially pediatric, administration

Publications (1)

Publication Number Publication Date
AR227201A1 true AR227201A1 (es) 1982-09-30

Family

ID=22660812

Family Applications (1)

Application Number Title Priority Date Filing Date
AR286473A AR227201A1 (es) 1980-08-22 1981-08-19 Procedimiento para preparar polvo capaz de ser reconstituido mediante el agregado de agua para dar una suspension farmaceuticamente microcapsulas de sal de adicion de acido de bacampicilina en un medio de suspension acuosa

Country Status (41)

Country Link
US (1) US4321253A (en])
JP (1) JPS5775986A (en])
KR (1) KR860000513B1 (en])
AR (1) AR227201A1 (en])
AT (1) AT370994B (en])
AU (1) AU529965B2 (en])
BE (1) BE890028A (en])
BG (1) BG42000A3 (en])
CA (1) CA1137414A (en])
CH (1) CH650674A5 (en])
CS (1) CS225845B2 (en])
DD (1) DD201644A5 (en])
DE (1) DE3132614C2 (en])
DK (1) DK158971C (en])
DZ (1) DZ315A1 (en])
ES (1) ES504905A0 (en])
FI (1) FI72647C (en])
FR (1) FR2488798A1 (en])
GB (1) GB2082539B (en])
GR (1) GR74983B (en])
HK (1) HK43786A (en])
HU (1) HU188679B (en])
IE (1) IE51506B1 (en])
IL (1) IL63617A (en])
IN (1) IN156538B (en])
IT (1) IT1138161B (en])
KE (1) KE3626A (en])
LU (1) LU83572A1 (en])
MX (1) MX5731A (en])
MY (1) MY8600597A (en])
NL (1) NL191978C (en])
NO (1) NO154821C (en])
NZ (1) NZ198106A (en])
PH (1) PH17125A (en])
PL (1) PL232141A1 (en])
PT (1) PT73555B (en])
RO (1) RO82679B (en])
SE (1) SE448819B (en])
SU (1) SU1364226A3 (en])
YU (1) YU43985B (en])
ZA (1) ZA815793B (en])

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH647676A5 (fr) * 1978-12-22 1985-02-15 Donald E Panoz Formes galeniques a usage oral, a liberation programmee et leurs procedes de preparation.
SE8103843L (sv) * 1981-06-18 1982-12-19 Astra Laekemedel Ab Farmaceutisk mixtur
SE8203953D0 (sv) * 1982-06-24 1982-06-24 Astra Laekemedel Ab Pharmaceutical mixture
US4994260A (en) * 1982-05-28 1991-02-19 Astra Lakemedel Aktiebolag Pharmaceutical mixture
EP0111560A4 (en) * 1982-06-14 1987-02-03 Key Pharma ASPIRINE WITH CONTINUOUS LEVEL.
US4508702A (en) * 1982-06-14 1985-04-02 Key Pharmaceuticals, Inc. Sustained release aspirin
DE3382392D1 (de) * 1982-07-09 1991-10-02 Key Pharma Dosierungsart zur dauerhaften verabreichung von chinidin.
US4634587A (en) * 1982-07-09 1987-01-06 Key Pharmaceuticals, Inc. Sustained release quinidine dosage form
AU569277B2 (en) * 1983-03-03 1988-01-28 Dow Chemical Company, The Aqueuos dispersion of water-insoluble organophilic cellulose ether for sustained release of active agents
US4555399A (en) * 1983-11-18 1985-11-26 Key Pharmaceuticals, Inc. Aspirin tablet
IE58110B1 (en) * 1984-10-30 1993-07-14 Elan Corp Plc Controlled release powder and process for its preparation
SE8405611D0 (sv) * 1984-11-09 1984-11-09 Astra Laekemedel Ab Process for stabilization of bacampicillin hydrochloride
US4800087A (en) * 1986-11-24 1989-01-24 Mehta Atul M Taste-masked pharmaceutical compositions
GB8628359D0 (en) * 1986-11-27 1986-12-31 Zyma Sa Galenical formulation
US4853229A (en) * 1987-10-26 1989-08-01 Alza Corporation Method for adminstering tiny pills
US5084278A (en) * 1989-06-02 1992-01-28 Nortec Development Associates, Inc. Taste-masked pharmaceutical compositions
RU2123863C1 (ru) * 1992-04-30 1998-12-27 Шеринг Корпорейшн Содержащая гидратированный цефтибутен порошковая антибактериальная композиция, предназначенная для орального использования в виде суспензии
US6270795B1 (en) 1995-11-09 2001-08-07 Microbiological Research Authority Method of making microencapsulated DNA for vaccination and gene therapy
US6270804B1 (en) * 1998-04-03 2001-08-07 Biovail Technologies Ltd. Sachet formulations
IN191482B (en]) * 1999-03-19 2003-12-06 Ranbaxy Lab Ltd
JP4711478B2 (ja) * 1999-08-13 2011-06-29 旭化成ケミカルズ株式会社 味がマスクされた薬物
US20050037086A1 (en) * 1999-11-19 2005-02-17 Zycos Inc., A Delaware Corporation Continuous-flow method for preparing microparticles
SK8562002A3 (en) 1999-12-23 2003-10-07 Pfizer Prod Inc Pharmaceutical compositions providing enhanced drug concentrations
EP1118333A1 (en) * 2000-01-18 2001-07-25 Eurand International S.P.A. Compositions with enhanced oral bioavailability
DE60128215T2 (de) 2000-04-20 2008-01-10 Novartis Ag Beschichtungszusammensetzung zur geschmacksmaskierung
US6551617B1 (en) 2000-04-20 2003-04-22 Bristol-Myers Squibb Company Taste masking coating composition
EP1292285A4 (en) * 2000-06-02 2009-07-22 Eisai Corp North America SYSTEMS FOR DISPENSING BIOACTIVE AGENTS
FR2822834B1 (fr) * 2001-04-02 2005-02-25 Flamel Tech Sa Suspension colloidale de nanoparticules a base de copolymeres amphiphile pour la vectorisation de principes actifs et leur mode de preparation
CA2447693A1 (en) * 2001-05-31 2002-12-05 Cima Labs Inc. Taste-masking of highly water-soluble drugs
KR20030015655A (ko) * 2001-08-17 2003-02-25 한미약품공업 주식회사 항암제의 경구흡수율을 증가시키는 인단계 화합물의결정성 산부가염, 이의 제조방법 및 이를 함유하는 약학적조성물
FR2830447B1 (fr) * 2001-10-09 2004-04-16 Flamel Tech Sa Forme galenique orale microparticulaire pour la liberation retardee et controlee de principes actifs pharmaceutiques
US8101209B2 (en) * 2001-10-09 2012-01-24 Flamel Technologies Microparticulate oral galenical form for the delayed and controlled release of pharmaceutical active principles
CA2480826C (fr) 2002-04-09 2012-02-07 Flamel Technologies Formulation pharmaceutique orale sous forme de suspension aqueuse de microcapsules permettant la liberation modifiee de principe(s) actif(s)
KR20050005437A (ko) * 2002-04-09 2005-01-13 플라멜 테크놀로지스 아목시실린의 변형 방출을 위한 마이크로캡슐 수성 현탁액형태의 경구 제약학적 제제
FR2842736B1 (fr) 2002-07-26 2005-07-22 Flamel Tech Sa Formulation pharmaceutique orale sous forme d'une pluralite de microcapsules permettant la liberation prolongee de principe(s) actif(s) peu soluble(s)
FR2842735B1 (fr) * 2002-07-26 2006-01-06 Flamel Tech Sa Microcapsules a liberation modifiee de principes actifs peu solubles pour l'administration per os
FR2843117B1 (fr) * 2002-07-30 2004-10-15 Flamel Tech Sa Polyaminoacides fonctionnalises par au moins un groupement hydrophobe et leurs applications notamment therapeutiques
US7632521B2 (en) * 2003-07-15 2009-12-15 Eurand, Inc. Controlled release potassium chloride tablets
FR2860516B1 (fr) * 2003-10-03 2006-01-13 Flamel Tech Sa Homopolyaminoacides telecheliques fonctionnalises par des groupements hydrophobes et leurs applications notamment therapeutiques
FR2862536B1 (fr) * 2003-11-21 2007-11-23 Flamel Tech Sa Formulations pharmaceutiques pour la liberation prolongee de principe(s) actif(s), ainsi que leurs applications notamment therapeutiques
US7244765B2 (en) * 2004-06-25 2007-07-17 Cytokine Pharmasciences, Inc Guanylhydrazone salts, compositions, processes of making and methods of using
FR2885526B1 (fr) * 2005-05-13 2007-07-27 Flamel Technologies Sa Medicament oral a base d'inhibiteur de pompe a protons
US20180177820A1 (en) * 2015-10-13 2018-06-28 Techno Guard Co. Ltd. Protective composition for gastrointestinal mucosa

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3549746A (en) * 1967-11-02 1970-12-22 Bristol Myers Co Antibiotic composition
US3873521A (en) * 1970-09-17 1975-03-25 Astra Laekemedel Ab Esters of {60 -amino penicillins
ZA718014B (en) 1970-12-23 1972-08-30 Beecham Group Ltd Pharmaceutical formulations
US4016254A (en) * 1972-05-19 1977-04-05 Beecham Group Limited Pharmaceutical formulations
GB1455296A (en) * 1973-05-24 1976-11-10 Beecham Group Ltd Veterinary treatment
GB1479655A (en) 1974-03-08 1977-07-13 Beecham Group Ltd Antibiotic preparations
US4127647A (en) * 1975-04-08 1978-11-28 Meiji Seika Kaisha, Ltd. Process for preparation of stable amorphous macrolide antibiotic solids
JPS5840529B2 (ja) * 1975-09-29 1983-09-06 明治製菓株式会社 ケイコウヨウセイザイノセイホウ
GB1561301A (en) * 1976-01-02 1980-02-20 Beecham Group Ltd Orally administrable pharmaceutical composition
ZA793934B (en) * 1978-08-04 1980-07-30 Beecham Group Ltd Powders
JPS57105316A (en) * 1980-12-23 1982-06-30 Hitachi Cable Ltd Method of fitting heat-shrinkable tube

Also Published As

Publication number Publication date
CS225845B2 (en) 1984-02-13
ZA815793B (en) 1982-08-25
AT370994B (de) 1983-05-25
MX5731A (es) 1993-11-01
CH650674A5 (fr) 1985-08-15
ES8303091A1 (es) 1983-02-01
LU83572A1 (fr) 1982-04-14
KR830005850A (ko) 1983-09-14
IL63617A (en) 1984-11-30
IE51506B1 (en) 1987-01-07
JPH0248525B2 (en]) 1990-10-25
FI812574L (fi) 1982-02-23
DK158971B (da) 1990-08-13
GB2082539A (en) 1982-03-10
FI72647C (fi) 1987-07-10
KE3626A (en) 1986-05-16
NZ198106A (en) 1983-12-16
ATA362781A (de) 1982-10-15
FI72647B (fi) 1987-03-31
NO812827L (no) 1982-02-23
YU201781A (en) 1984-04-30
FR2488798B1 (en]) 1985-01-11
IL63617A0 (en) 1981-11-30
CA1137414A (en) 1982-12-14
BG42000A3 (en) 1987-09-15
ES504905A0 (es) 1983-02-01
YU43985B (en) 1990-02-28
NL191978B (nl) 1996-08-01
DK158971C (da) 1991-01-07
DE3132614C2 (de) 1985-08-22
IT1138161B (it) 1986-09-17
DE3132614A1 (de) 1982-05-19
RO82679A (ro) 1984-05-23
BE890028A (fr) 1982-02-22
NL191978C (nl) 1996-12-03
IN156538B (en]) 1985-08-31
MY8600597A (en) 1986-12-31
JPS5775986A (en) 1982-05-12
GR74983B (en]) 1984-07-12
IT8123587A0 (it) 1981-08-20
PT73555B (en) 1983-07-14
KR860000513B1 (ko) 1986-05-02
SU1364226A3 (ru) 1987-12-30
IE811911L (en) 1982-02-22
NO154821C (no) 1987-01-07
GB2082539B (en) 1984-01-18
SE448819B (sv) 1987-03-23
HU188679B (en) 1986-05-28
PT73555A (en) 1981-09-01
DZ315A1 (fr) 2004-09-13
HK43786A (en) 1986-06-20
SE8104974L (sv) 1982-02-23
DD201644A5 (de) 1983-08-03
RO82679B (ro) 1984-07-30
AU529965B2 (en) 1983-06-30
DK372181A (da) 1982-02-23
PL232141A1 (en]) 1982-03-15
PH17125A (en) 1984-06-01
NL8103902A (nl) 1982-03-16
AU7441681A (en) 1982-04-01
FR2488798A1 (fr) 1982-02-26
US4321253A (en) 1982-03-23
NO154821B (no) 1986-09-22

Similar Documents

Publication Publication Date Title
AR227201A1 (es) Procedimiento para preparar polvo capaz de ser reconstituido mediante el agregado de agua para dar una suspension farmaceuticamente microcapsulas de sal de adicion de acido de bacampicilina en un medio de suspension acuosa
ES553714A0 (es) Procedimiento para la preparacion de una composicion que contiene una sal de acido hialuronico.
IT1178223B (it) Sistema per modificare l'assetto di un veicolo dalla conduzione con due ruote motrici a quattro ruote motrici
FI961739A0 (fi) Amiinisuoloja klavulaanihapon valmistamiseksi
GB8311345D0 (en) Oral administration of capsules to animals
IT1143248B (it) Procedimento per la preparazione di sospensioni stabili e non gelificanti a base di sali inorganici e zeoliti in particolare per la produzione di detersivi in granuli
ES521692A0 (es) Un procedimiento para la preparacion de (-)-(r)-1-hidroxi-2--(r-1-metil-3-fenilpropril-aminoetil-salicilamida o una sal de adicion de acido respectiva.
DE3163511D1 (en) Preparation of the calcium salt of alpha-hydroxy-gamma-methylmercaptobutyric acid
ZA909949B (en) Injectable formulations containing the sodium salt of naproxen
JPS5726641A (en) Use of substituted derivative of 4-phenyl-4-oxo-2-butenoic acid as drug
IT1142096B (it) Derivati dell'acido 7-acilammino cefalosporanico e procedimenti per la loro preparazione
IT1126544B (it) Procedimento per la preparazione di derivati dell'acido 7-amino-desacetossi cefalosporanico
IT8119831A0 (it) Procedimento per la preparazione dell'acido 7-(d(-)-alfa-ammino-p.idrossifenilacetammido)desacetossicefalosporanico.
GB2104509B (en) New synthetic route to optically active 2-penem-3-carboxylic acid derivatives
FR2545678B1 (fr) Cultivateur equipe de roues de terre accroissant sa stabilite
ITTO930761A1 (it) Fiala a soluzione per infusione di acido tiottico in forma di sale idrosolubile dell'acido tiottico.
PL301623A1 (en) Cephalosporin salts, method of obtaining such salts as well as pharmaceutical preparation containing them
JPS56140968A (en) Manufacture of carbamoylsulfonic acid derivative salt
IT1199103B (it) Procedimento per la preparazione dell'acido 1-naftol-4-solfonico
IT1155201B (it) Procedimento per la preparazione di un derivato dell'acido cefalosporanico
IT8024849A0 (it) Procedimento per la preparazione di derivati dell'acido 7-amminocefalosporanico.
ES537074A0 (es) Un procedimiento para la preparacion de una sal de s-adenosil-l-metionina
PL276865A1 (en) Preparation method for sodium salt of the 7/z-2-(aminetiazolile-4)2-metoxyiminoacetylamine/-cephalospornic acid
IT8548980A0 (it) Procedimento per la preparazione di sali dell'acido ialuronico
IT1167484B (it) Procedimento per la preparazione dell'acido 7-(d-alfa-fenilglicilamido)-3-cloro-3-cefem-4-carbossilico